Operating cash flow of -$50.3M in 2026Q3 tracked net losses closely (OCF/NI near 1.08), with CapEx below 0.1% of revenue and no dividends or buybacks, indicating cash consumption is driven almost entirely by clinical operations.
Dianthus Therapeutics, Inc. (DNTH) cash flow statement — 10-year operating, investing & financing cash flows
| Metric | TTM | Dec'25 | Dec'24 | Dec'23 | Dec'22 | Dec'21 | Dec'20 | Dec'19 | Dec'18 | Dec'17 | Dec'16 |
|---|
| Cash from Operations | -175.15M | -129.06M | -78.18M | -36.86M | -29.07M | -59.53M | -64.02M | -57.1M | -41.89M | -22.26M | -6.53M |
| Operating CF Margin % | - | -6338.9% | -1253.89% | -1304.35% | -453.02% | -4033.27% | - | - | - | - | - |
| Operating CF Growth % | -245.38% | -65.08% | -112.09% | -26.8% | 51.17% | 7.02% | -12.12% | -36.33% | -88.14% | -240.99% | - |
| Net Income | -39.79M | -162.34M | -84.97M | -43.55M | -28.48M | -71.14M | -74.94M | -76.77M | -57.52M | -35.49M | -9.43M |
| Depreciation & Amortization | 317K | 428K | 412K | 355K | 147K | 2.02M | 1.98M | 1.84M | 875K | 376K | 6K |
| Stock-Based Compensation | 41.2M | 22.79M | 12.89M | 2.9M | 1.52M | 0 | 0 | 0 | 0 | 2.26M | 662K |
| Deferred Taxes | 0 | 0 | 0 | -661K | 0 | 0 | -12.95M | -13.54M | 0 | 0 | 0 |
| Other Non-Cash Items | -8.62M | -6.67M | -6.17M | -762K | -606K | 11.11M | 23.07M | 22.53M | 10.02M | 13.41M | 306K |
| Working Capital Changes | -5.93M | 16.73M | -351K | 4.86M | -1.65M | -1.53M | -1.19M | 8.83M | 3.98M | 1.32M | 1.6M |
| Change in Receivables | 4.42M | 755K | 0 | 5.16M | -4.16M | 0 | 0 | 0 | 0 | 0 | 0 |
| Change in Inventory | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Change in Payables | 691K | 11.28M | 8.19M | 661K | 2.28M | -720K | 948K | 145K | 2.5M | -1.13M | 1.01M |
| Cash from Investing | -687.16M | -122.83M | -286.81M | 20.25M | -59.82M | 43.43M | -10.63M | 1.53M | -91.7M | -2.2M | -139K |
| Capital Expenditures | -697K | -213K | -105K | -110K | -139K | -1.26M | -400K | -3.06M | -7.67M | -2.2M | -139K |
| CapEx % of Revenue | 25.64% | 10.46% | 1.68% | 3.89% | 2.17% | 85.64% | - | - | - | - | - |
| Acquisitions | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 12K | 0 | 0 |
| Investments | - | - | - | - | - | - | - | - | - | - | - |
| Other Investing | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 12K | -135K | 0 |
| Cash from Financing | 862.15M | 280.13M | 255.62M | 133.57M | 96.68M | 89.6M | 67.74M | 62.3M | 142.15M | 71.49M | 10.71M |
| Debt Issued (Net) | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 6.5M |
| Equity Issued (Net) | -102.64M | 280.13M | 269.2M | 72M | 100M | 89.6M | 67.74M | 62.3M | 142.15M | 71.49M | 4.21M |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Share Repurchases | 317K | 0 | 0 | 0 | 0 | 0 | 0 | 0 | -88K | -213K | -107K |
| Other Financing | 964.78M | 0 | -13.57M | 61.57M | -3.32M | 0 | 0 | 0 | 0 | 0 | 0 |
| Net Change in Cash | -169K | 28.23M | -109.37M | 116.97M | 7.79M | 73.5M | -6.92M | 6.73M | 6.78M | 47.02M | 4.04M |
| Free Cash Flow | -175.85M | -129.27M | -78.28M | -36.97M | -29.21M | -60.8M | -64.42M | -60.16M | -49.56M | -24.46M | -6.67M |
| FCF Margin % | -6469.87% | -6349.36% | -1255.57% | -1308.24% | -455.18% | -4118.9% | - | - | - | - | - |
| FCF Growth % | -60.41% | -65.13% | -111.75% | -26.57% | 51.95% | 5.63% | -7.08% | -21.4% | -102.59% | -266.86% | - |
| FCF per Share | -3.07 | -3.42 | -2.35 | -7.17 | -7.79 | -17.70 | -23.47 | -26.01 | -23.80 | -11.07 | -3.02 |
| FCF Conversion (FCF/Net Income) | 4.42x | 0.80x | 0.92x | 0.85x | 1.02x | 4.54x | 0.85x | 0.74x | 0.73x | 0.63x | 0.69x |
| Interest Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Taxes Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Quick answers to the most common questions about buying DNTH stock.
Dianthus Therapeutics, Inc. (DNTH) generated $-129.1M in net cash from operating activities in 2025. This reflects the cash generated directly from core business operations.
Dianthus Therapeutics, Inc. (DNTH) reported negative free cash flow of $129.3M in 2025, indicating capital requirements exceeded cash from operations.
Dianthus Therapeutics, Inc. (DNTH) spent $0.2M on capital expenditures in 2025. CapEx represents the cash invested in physical assets like property, plant, and equipment to maintain or grow the business.
Key Metrics
Top Statement Risk
Cash runway shortfall and dilution
Metrics are mathematically derived from official filings.
Operating Cash Burn Tracks Losses Closely
According to reported quarterly figures, DNTH's operating cash flow has tracked net losses closely, with the OCF-to-net-income ratio near 0.7 to 1.1 across most recent quarters, indicating losses are largely cash-driven rather than accrual-driven.
The ratio of operating cash flow to net income sits near 1.0 in most quarters, which suggests the reported losses are substantially real cash outflows rather than non-cash charges. The 2025Q4 net income of $97.9M against operating cash flow of -$47.0M, however, produces a negative ratio that appears to reflect a large non-operating gain unrelated to core clinical spending. Investors should treat that single quarter as an earnings-quality anomaly rather than evidence of improving conversion.
Free Cash Flow Deeply Negative and Accelerating
Based on reported figures, DNTH's free cash flow deteriorated to -$50.7M in 2026Q3, with FCF margins sitting between -42% and -166% across recent quarters against a tiny legacy revenue base.
Because revenue has largely wound down, FCF margins are mathematically extreme and carry limited analytical meaning beyond confirming the absence of a self-funding business model. The absolute quarterly burn has roughly doubled from around $14.5M in 2024Q2 to over $50M in the latest two quarters, which suggests spending is scaling faster than any income base. The trajectory points toward a rapidly shortening runway rather than a stabilizing cost structure.
Minimal Capital Intensity Confirms Asset-Light Model
As reported in cash flow statements, DNTH's capital expenditures remained negligible, with CapEx below 0.1% of revenue in most quarters and at most $368K in 2026Q3, consistent with outsourced clinical development.
The low capital expenditure profile is consistent with a company that relies on contract research organizations and manufacturing partners rather than owned infrastructure. Capex is therefore not a meaningful use of cash, and nearly the entire burn reflects operating spending on clinical programs. This structure reduces fixed-asset risk but increases dependence on external vendors and trial timelines.
Cash Consumed Entirely by Clinical Operations
Per the reported cash flow data, DNTH paid no dividends and recorded no meaningful buybacks, with the only cash deployment directed at operating activities that consumed roughly $50M per quarter in recent periods.
The absence of dividends and repurchases is appropriate for a clinical-stage entity with negative free cash flow, and it means the full burn is directed toward pipeline development. There is no evidence in the supplied data of acquisitions or debt paydown absorbing capital. The implication is that every dollar of the reported $51 million cash balance is effectively committed to clinical execution, leaving little buffer against trial delays or cost overruns.
Cash Runway Constraint Warrants Monitoring
Based on reported figures, DNTH's roughly $51M cash balance against a quarterly operating burn near $50M suggests a runway potentially under one year, which may indicate a near-term financing event is likely.
If quarterly burn persists near the latest $50M level, the reported cash position would be exhausted within roughly one quarter, a conclusion that is sensitive to the completeness of the cash figure and any undisclosed committed funding, which the supplied data does not confirm. Investors should monitor for a capital raise or partnership announcement, as dilution appears the most probable near-term outcome. Any unreported financing access or cost reduction would materially change this inference, and the absence of forward guidance in the latest report limits confidence in the timing.